Document:

CONVERTIBLE
PROMISSORY NOTE

 

THIS
NOTE AND ANY SHARES OF STOCK ISSUABLE UPON THE CONVERSION HEREOF HAVE NOT BEEN REGISTERED
UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THIS NOTE·AND ANY
SHARES OF STOCK ISSUABLE UPON THE CONVERSION HEREOF MAY NOT BE SOLD, OFFERED FOR SALE, MORTGAGED, PLEDGED, HYPOTHECATED OR OTHERWISE
TRANSFERRED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT COVERING THIS NOTE OR SUCH SHARES UNDER SAID ACT AND APPLICABLE
STATE SECURITIES LAWS OR THE DELIVERY OF AN OPINION OF COUNSEL THAT SUCH REGISTRATION IS NOT REQUIRED. THIS NOTE IS ALSO SUBJECT
TO RESTRICTIONS ON TRANSFER.

 

REGEN
BIOPHARMA, INC.

 

	Issue Date: September 22,
    2017	 	Principal
    Amount: $50,000

 

 

1.     
Terms. For
value received, the Regen BioPharma, Inc., a Nevada corporation (the "Company") hereby absolutely and unconditionally
promises to pay to the order of________, an individual (the "Lender") ON DEMAND AT ANY TIME AFTER September 21, 2020
{the "Maturity Date"), the principal amount of Fifty Thousand Dollars ($50,000) and interest on the :whole amount of
said principal sum outstanding and remaining from time to time unpaid (the "Note"), commencing from the date hereof
and continuing until payment in full of this Note or conversion as hereinafter provided, at an annual rate equal to ten percent
(I 0%) simple interest. Interest shall be payable quarterly upon demand or upon conversion pursuant to Section 2 hereunder. Interest
shall be computed on the basis of the actual number of days elapsed divided by 365. Principal and interest shall be payable in
lawful money of the United States of America, at the principal place of business of the Lender or at such other place as the Lender
may have designated from time to time in writing to the Company.

 

		2.	Conversion.

 

2.1  
Conversion Right. The Lender shall have the right from time to time to convert all or a part of the outstanding and unpaid
principal amount of this Note and all or part of the outstanding and unpaid accrued interest of this Note into fully paid and
non-assessable shares of Common Stock, as such Common Stock exists on the Issue Date, or any shares of capital stock or other
securities of the Company into which such Common Stock shall hereafter be changed or reclassified at the conversion price (the
"Conversion Price") determined as provided herein (a "Conversion").

 

The
Lender shall have the right to convert one hundred percent (I 00%) of the Principal Amount and any accrued interest commencing
as of the date which is the earlier of:

 

(i)
One day subsequent to the execution of an agreement
to a transaction whose completion would result in a "Change of Control" of the Company. For purposes of this Note, a
Change of Control shall be defined as any transaction or serie of transactions, whether by merger, sale of substantially all of
the assets, or sale or transfer of more than fifty percent (50%) of the outstanding stock of the relevant entity . in which the
members of the Board of Directors immediately preceding the closing of the Change of Control transaction no longer constitute
a majority of the Board of Directors of the surviving entity following the closing of such transaction.

 

    	 	1	 

     

    

 (ii) 
One day subsequent to the execution of an agreement to a transaction whose completion would result in a "Change of
Control" of KCL Therapeutics, Inc. For purposes of this Note, a Change of Control shall be defined as any transaction or
series of transactions, whether by merger, sale of substantially all of the assets, or sale or tra11-sfer of more than fifty percent
(50%) of the outstanding stock of the relevant entity in which the members of the Board of Directors immediately preceding the
closing of the Change of Control transaction no longer constitute a majority of the Board of Directors of the surviving entity
following the closing of such transaction.

 

(iii)        
One day subsequent to the commencement, in compliance
with applicable law, of a broad sol citation by a third party to purchase a majority percentage of the Company's outstanding equity
securities for a limited period of time contingent on shareholders of the Company tendering a fixed number of their equity securities
("Tender Offer").

 

(iv)
One day subsequent to the execution of an agreement that could result in a Transaction Event:

 

"Transaction
Event" shall mean either of:

 

(a) 
The sale by the Company or by KCL Therapeutics,
Inc. of any or all of the Company's proprietary NR2F6 intellectual property to an unaffiliated third party

 

(b)  
The granting of a license by the Company or by
KCL Therapeutics, Inc. to an unaffiliated third party granting that unaffiliated third party the right to develop and/or commercialize
any or all of the Company's proprietary NR2F6 intellectual property

 

lf
e execution of the agreement resulting in a Transaction Event shall result in a closing of the Transaction Event prior to 30
days subsequent to the execution of the agreement, the right to convert under this subsection (iv) shall be 30
days prior to the closing to the Transaction Event, and the Company shall provide the Lender with a Notice of Right to
Convert at least 30 days pri6rto the.closing of the Transaction Event.

 

(v)       That
date which is twenty four (24) months subsequent to the date of execution of this Note.

 

The
number of shares of Common Stock to be issued upon each conversion of this Note shall be determined by dividing the principal
amount of this Note to be converted (the "Conversion Amount") by the applicable Conversion Price as defined in this
Section 2 then in effect on the date specified in the notice of conversion, in the form attached hereto as Exhibit A (the "Notice
of Conversion"), delivered to the Company by the Lender on such conversion date (the "Conversion Date").

 

    	 	2	 

     

    

 

2.2
Conversion Price.The "Conversion Price" shall be defined as the lower $0.0125 per share, or, a75% discount
to the closing price of the Common Stock on the Over-the-Counter Bulletin Board on the trading day immediately prior to the date
that a Notice of Conversion is submitted pursuant to Section 2.3. or, if the Over-the-Counter Bulletin Board is not the principal
trading market for such security, the closing price of such security on the principal securities exchange or trading market where
such security is listed or traded on the trading day immediately prior to the date that a Notice of Conversion is submitted pursuant
to Section 2.3. or, if no closing bid price of such security is available in any of the foregoing manners, the average of the
closing bid prices of any market makers for such security that are listed in the "pink sheets" by the National Quotation
Bureau, Inc. on the trading day immediately prior to the date that a Notice of Conversion is submitted pursuant to Section 2.3.

 

2.3  
Method of Conversion. Subject to Section 2.1, this Note may be converted by the Lender by submitting to the Company a Notice
of Conversion by facsimile, e-mail or other reasonable me s of communication dispatched on the Conversion Date prior to 5:00 p.m.,
New York, New York time. The Lender shall not be required to physically surrender this Note to the Company unless the entire unpaid
principal amount of this Note is so converted. The Lender and the Company shall maintain records showing the principal amount
so converted and the dates of sucth conversions so as not to require physical surrender of this Note upon each such conversion.
In the event of any dispute or discrepancy, such records of the Company shall, prima facie, be controlling and determinative in
the absence of manifest error. Notwithstanding the foregoing, if any portion of this Note is converted as aforesaid, the Lender
may not transfer this Note unless the lender first physically surrenders this Note to the Company, whereupon the Company will
forttwith issue and deliver upon the order of the Lender a new Note of like tenor, registered as the i Lender (upon
payment by the Lender of any applicable transfer taxes) may request, representing in the aggregate the remaining unpaid
principal amount of this Note.

 

Upon
receipt by the Company from the Lender of a facsimile transmission, e-mail, or other reasonable means of communication of a Notice
of Conversion meeting the requirements for !conversion, the Company shall issue and deliver or cause to be issued and delivered
to or upon the order. of the Lender certificates for the Common Stock issuable upon such conversion within ten (10) business days
after such receipt. Upon receipt by the Company of a Notice of Co version, the Lender shall be deemed to be the Lender of record
of the Common Stock issuable upon such conversion, the outstanding principal amount and the amount of accrued and unpaid interest
on this Note shall be reduced to reflect such conversion. All rights with respect to the portion of this Note being so converted
shall forthwith terminate except the right to receive the: Common Stock or other securities as herein provided on such conversion.
In lieu of delivering physical certificates representing the Common Stock issuable upon
conversion, provided the .Company is participating in the Depository Trust Company ("DTC") Fast Automated Securities
Transfer ("FAST") program, upon request of the Lender, the Company shall use its best efforts to cause its transfer
agent to electronically transmit the Common Stock issuable upon conversion to the Lender by crediting the account of Lender's
Prime Broker with DTC through its Deposit Withdrawal Agent Commission ("DWAC") system.

 

2.4
Concerning the Shares. The shares of Common Stock issuable upon conversion of this Note may not be sold or transferred unless
(i) such shares are sold pursuant to an effective registration statement under the Act or (ii) the Company or its transfer agent
shall have been furnished with an opinion of counsel (which opinion shall be in form, substance and scope customary for opinions
of counsel in comparable transactions) to the effect that the shares to be sold or transferred may be sold or transferred pursuant
to an exemption from such registration or (iii) such shares are sold or transferred pursuant to Rule 144 under the Act (or a successor
rule) ("Rμle 144") or (iv) such shares are transferred to an "affiliate" (as defined in Rule 144) of
the Company who agrees to sell or otherwise transfer the shares only in accordance with this Section 2.5; and who is an Accredited
Investor as the term Accredited Investor is defined in Rule 501 of Regulation D, promulgated under the Act.

    	 	3	 

     

    

 

Subject
to the removal provisions set forth below, until such time as the shares of Common Stock issuable upon conversion of this Note
have been registered under the Act or otherwise may be sold pursuant to Rule 144 without any restriction as to the number of securities
as of a particular date that can then be immediately sold, each certificate for shares of issuable upon conversion of this Note
that has not been so included in an effective registration statement or that has not been sold pursuant to an effective registration
statement or an exemption that permits removal of the legend, shall bear a legend substantially in the following form, as appropriate:

 

"NEITHER
THE ISSUANCE OR SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAS BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN
THE ABSENCE OF (A) AN EF ECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR (B)
AN OPINION OF COUNSEL (WHICH COUNSEL SHALL BE SELECTED BY THE LENDER), IN A GENERALLY ACCEPTABLE FORM, THAT REGISTRATIO:N IS NOT
REQUIRED UNDER SAID ACT."

 

The
legend set forth above shall be removed and the Company shall issue to the Lender a new certificate therefore free of any transfer
legend if (i) the Company or its transfer agent shall have received an opinion of counsel, in form, substance and scope customary
for opinions of counsel in comparable transactions, to the effect that a public sale or transfer of such Common Stock may be made
without registration under the Act and the shares are so sold or transferred, (ii) suci1 Lender provides the Company or its transfer
agent with reasonable assurances that the Common Stock issuable upon conversion of this Note (to the extent such securities are
deemed to have been acquired on the same date) can be sold pursuant to Rule 144 or (iii) in the case of the Common Stock issuable
upon conversion of this Note, such security is registered for sale by unc(er an effective registration statement filed under the
Act or (iv) otherwise may be sold pursuant to Rule 144 without any restriction as to the number of securities as of a particular
date that can then be immediately sold.

 

2.5   
Reverse Stock Splits. If the number of shares of Common Stock outstanding at any time while this Not is outstanding is
decreased by a combination of the outstanding shares of Common Stock, then, following the record date of such combination, the
Conversion Price shall be appropriately increased so that the number of shares of Common
Stock issuable on conversion hereof shall be decreased in proportion to such decrease in outstanding shares.

 2.6
Stock Dividends and Stock Splits. If the Company, at any time while this Note is outstandings ubdivides outstanding shares
of Common Stock into a larger number of shares then the Conversion price shall be multiplied by a fraction of which the numerator
shall be the number of shares of Common Stock (excluding any treasury shares of the Company) outstanding immediately before such
event and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event

 

    	 	4	 

     

    

 

3.
Payment.

 

 

WIRE
INSTRUCTIONS:

4.          
Prepayment. Notwithstanding anything to the contrary contained herein, the Company shall have the right, exercisable on
not less than ten (10) Trading Days prior written notice to the Lender, to prepay the outstanding Note in part or in full, including
outstanding principal and accrued interest. Any notice of prepayment hereunder shall be delivered to the Lender at its registered
addresses and shall state that the Company is exercising its right to prepay the Note and the date of prepayment, which shall
be not more than ten (10) Trading Days from the date of the prepayment notice. Upon receipt of a prepayment notice, Lender shall
have the :right, but not the obligation, to accelerate the conversion period specified in Section 2.1 and convert that portion
of the outstanding principal balance which is subject to prepayment to Common Shares as provided for in Section 2.

 

5.
Warrant Coverage. In the event that that the Company exercises its right to prepay the Note, or if the Lender chooses not
to convert the remaining amount of the note into Common Shares of the company, the Lender shall receive warrants equal to 10%
of the Common shares it would have received had the Lender converted the remaining amount of the Note into Common shares of the
Company. The warrants shall have a strike price of $0.0125 per share. See Exhibit B (incorporated into this Note) for instructions
on completing the Exercise of Warrants document.

 

6.   
Events of Default.

 

6.1
The following shall constitute events of default (individually an "Event of Default"):

 

(a)
default in the payment, when due or payable, of an obligation to pay interest or principal under this Note, which default is not
cured by payment in full of the amount due within thirty (30) days om the date that the Lender receives notice of the occurrence
of such default;

 

(b)
filing of a petition in bankruptcy or the commencement of any proceedings under any bankruptcy laws by or against the Company,
which filing or proceeding, is not dismissed within ninety (90) days after the filing or commencement thereof; or

 

(c) 
failure of the
Company to
comply
in any
way with the terms,
covenants or conditions contained in
this Note.

    	 	5	 

     

    

 

6.2
If an Event
of Default shall
occur and
be continuing, the
Lender may,
at its option,
declare trus Note
to be immediately due and
payable without
further notice or
demand, wh re upo n
this Note
shall become immediately
due and payable without
presentment, demand or
protest, all of
which are hereby
waived by the Company.

 

7.   
Transfer of
Note. This
Note may not be
transferred or
assigned other than a
transfer or assignment to
an Affiliate of the
Lender. As used herein,
the term
" Affiliate"
means an entity
that directly, or
indirectly through one
or more intermediaries, controls,
or is
controlled by,
or is
under common control
with, the Lender.

8.
Certain Waivers. The
Company hereby
expressly
and
irrevocably waives
presentment, demand, protest,
notice of
protest and
any other formalities of any
kind.

 

9.
Amendment, Modification or
Termination. This
Note may
only be
modified, amended, or
terminated (other
than by payment in full)
by an
agreement in
writing
signed by the Company and
the Lender. No
waiver of any term, covenant
or provision of this
Note shall be effective unless
given in writing by
the
Lender.

 

10.
Governing Law.
This Note and
the obligations
of the Company
hereunder
shall be
governed by
and interpreted
and determined
in accordance with the laws of
the State of California (excluding
the
laws
ru1d rules
of law
applicable
to conflicts
or choice of law).

 

IN
WITNESS WHEREOF, this Note
has been duly
executed on
behalf of the
un ersigned on
the day and
in the
year first above
written.

 

 

	REGEN BIOPHARMA, INC	 	 
	 	 	 
	/s/ David R. Koos	 	9/25/2017
	Chairman and CEO	 	Date

 

The
foregoing Convertible
Promissory Note is
hereby accepted and agreed to
by the
undersigned on and as
of the date first above
written.

 

_______,
an individual

 

 

    	 	6	 

     

    

 

 

EXHIBIT
A NOTICE OF CONVERSION

 

The
undersignedhereby elects to convert$ __________ principalamountand $ __________ accrued interest of the Note into
that number of shares of Common Stock to be issued pursuant to the conversion of the Note as set forth below of REGEN BIOPHARMA.
INC. according to the conditions of the convertible note of the Company dated as of Month XX 2020 as of the date written below.

 

	Date of Conversion:	 	 
	Applicable Conversion Price:	 	 
	(Attach
    Bloomberg price documentation)	 
	Number of Shares of Common Stock to be Issued
    Pursuant to Conversion of the Note:	 	 
	 	 	 
	Amount of Principal Balance Due Remaining Under
    the Note After This Conversion:	 	 

 

Checked
box corresponds to applicable instructions:

 

	☐ 	The Borrower shall electronically
    transmit the Common Stock issuable pursuant to this Notice of Conversion to the account of the undersigned or its nominee
    with OTC through its Deposit Withdrawal Agent Commission system (“Wire Transfer”)
	 	 	 
	 	Name of DTC Prime Broker:	 	 
	 	Account Number:	 	 
	 	 	 
	☐ 	The undersigned hereby requests
    that the Borrower issue a certificate or certificates for the number of shares of Common Stock set forth below in the name(s)
    specified immediately below or, if additional space is necessary, on an attachment hereto:
	 	 	 
	 	Name:	 	 
	 	Address:	 	 
	 	 	 	 
	 	 	 	 
	 	Phone:	 	 

 

	 	 	 
	Name	 	Date
	Title	 	 

 

 

    	 	7	 

     

    

 

EXHIBIT
B

 

COMMON
STOCK PURCHASE WARRANT REGEN BIOPHARMA, INC.

 

THIS
WARRANT AND THE SHARES ISSUABLE UPON EXERCISE OF THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.
THIS WARRANT AND THE SHARES ISSUABLE UPON EXERCISE OF THIS WARRANT MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED
IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT OR APPLICABLE EXEMPTION OR SAFE HARBOR PROVISION.

 

 

THIS
COMMON STOCK PURCHASE WARRANT (the "Warrant") certifies that, for value received, Lender is entitled, solely upon the
terms and subject to the limitations on exercise and the :conditions hereinafter set forth, to subscribe for and purchase from
the Company, shares of common stock of the Company (the "Warrant Shares"). The purchase price of one Warrant Share under
this Warrant shall be equal to the $0.0125 per Warrant Share ("Exercise Price").

 

1.
In the event that Company shall exercise Company's
rights pursuant to Section 4 of the Note ("Prepayment Clause") , Lender shall be entitled , on or prior to the close
of business on the three (3) month anniversary of the date that the Note shall have been prepaid by the Company ("Prepayment
Date'') , to subscribe for and purchase from the Company up to that number of Warrant Shares at the Exercise Price per Share equivalent
to that one tenth of that number of Common Shares that Lender would have been entitled to be issued had Lender exercised Lender's
Conversion Right pursuant to Section 2.1 of the Note as of the Prepayment Date.

 

2.
In the event that, as of the Maturity Date, part of the outstanding and unpaid principal amount of this Note and any Accrued Interest
remains outstanding, Lender shall be entitled, on or prior to the close of business on the three (3) month anniversary of the
Maturity Date, to subscribe for and purchase from the Company up to that number of Warrant Shares at the Exercise Price per Share
equivalent to that one tenth of that number of Common Shares that Lender would have been entitled to be issued had Lender exercised
Lender's Conversion Right pursuant to Section 2.1 of the Note as of the Maturity Date.

 

3.
If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or otherwise makes a distribution or
distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares of Common Stock
(which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon exercise of this Warrant),
(ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including by way of reverse
stock split) outstanding shares of Common Stock into a smaller number of shares or (iv) issues by reclassification of shares of
the Common Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction
of which the numerator shall be the number of shares of Common Stock (excluding treasury shares, if y)outstanding immediately
before such event and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such
event, and the number of shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate
Exercise Price of this Warrant shall remain unchanged. Any adjustment made pursuant to this Section 3 shall become effective immediately
after the record date for the determination of stockholders entitled to receive such dividend or distribution and shall become
effective immediately after the effective date in the case of a subdivision, combination or reclassification

 

    	 	8	 

     

    

4.
Exercise of the purchase rights represented
by this Warrant may be made, in whole or in part, from and after the initial exercise date, and then at any time, by delivery
to the Comp8!J.y (or such other office or agency of the Company as it may designate
by notice in writing to-Lender at the address of the Lender appearing on the books of the Company) of a duly executed facsimile
or emailed copy of the Notice of Exercise form annexed hereto and delivery of the aggregate Exercise Price for the Warrant Shares
specified in the applicable Notice of Exercise by wire transfer.

 

5.
Warrant Shares purchased hereunder will be delivered
to Holder within 10 business days of Notice of Exercise.

 

6.
The Warrant Shares may not.be sold or transferred unless (i) such shares are sold pursuant to an effective registration statement
under the Act or (ii) the Company or its transfer agent shall have been furnished with an opinion of counsel (which opinion shall
be in form, substance and scope customary for opinions of counsel in comparable transactions) to the effect that the shares to
be sold or transferred may be sold or transferred pursuant to an exemption from such registration or (iii) such shares are sold
or transferred pursuant to Rule 144 under the Act (or a successor rule) ("Rule 144") or (iv) such shares are transferred
to an "affiliate" (as defined in Rule 144) of the Company who agrees to sell or otherwise transfer the shares only in
accordance with this Section 6 and who is an Accredited Investor as the term Accredited Investor is defined in Rule 50l of Regulation
D, promulgated under the Act. subject to the removal provisions set forth below, until such time as the Warrant Shares have been
registered wider the Act or otherwise may be sold pursuant to Rule 144 without any restriction
as to the number of securities as of a particular date that can then be immediately sold,
each certificate for Warrant Shares that have not been so included in an effective registration statement or that have not been
sold pursuant to an effective registration statement orexemption that permits removal of the legend, shall bear a legend substantially
in the following form, as appropriate:

 

"NEITHER
THE ISSUANCE OR SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAS BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (l) IN
THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR (B)
AN OPINION OF COUNSEL (WHICH COUNSEL SHALL BE SELECTED BY THE LENDER), IN A GENERALLY ACCEPTABLE FORM, THAT REGISTRATION IS NOT
REQUIRED UNDER SAID ACT."

    	 	9	 

     

    

 

 

The
legend set forth above shall be removed and the Company shall issue to the Lender a new certificate therefore free of any transfer
legend if (i) the Company or its transfer agent Shall have received an opinion of counsel, in form, substance and scope customary
for opinions of counsel in comparable transactions, to the effect that a public sale or transfer of such securities may be made
without registration under the Act and the shares are so sold or transferred, (ii) such Lender provides the Company or its transfer
agent with reasonable assurances that the Warrant Shares can be sold pursuant to Rule 144 or (iii) such security is registered
for sale by under an effective registration statement filed under the Act or (iv) otherwise may be sold pursuant to Rule 144 without
any restriction as to the number of securities as of a particular date that can then be immediately sold.

 

7.
The Lender shall not be required to physically surrender this Warrant to the Company. If the Lender has purchased all of the Warrant
Shares available hereunder and the Warrant has been exercised in full, this Warrant shall automatically be cancelled without the
need to surrender the Warrant to the Company for cancellation.

 

8.
This Warrant may not be transferred or assigned other than a transfer or assignment to an Affiliate of the Lender. As used herein,
the term "Affiliate" means an entity that directly, or indirectly through one or more intermediaries, controls, or is
controlled by, or is under common control with, the Lender.

 

9.
FORM OF WARRANT NOTICE

 

NOTICE
OF EXERCISE

 

To:
REGEN BIOPHARMA, INC.

 

The
undersigned hereby elects to purchase __________ Warrant Shares of the Company pursuant to the terms of the Warrant issued in
connection with that Convertible Note in the amount of ___ by and between __________ and the Company dated __________ and maturing
_____,2020 and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.

 

Please
issue a certificate or certificates representing said Warrant Shares in the name of the undersigned. The undersigned is an "accredited
investor" as defined in Regulation D promulgated under the Securities Act of 1933, as amended.

 

[SIGNATURE]

 

	Name:	 
	Date:	 

 

    	 	10CONVERTIBLE
PROMISSORY NOTE

THIS
NOTE AND ANY SHARES OF STOCK ISSUABLE UPON THE CONVERSION HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THIS NOTE AND ANY SHARES OF STOCK ISSUABLE UPON THE CONVERSION HEREOF MAY NOT BE
SOLD, OFFERED FOR SALE, MORTGAGED, PLEDGED, HYPOTHECATED OR OTHERWISE TRANSFERRED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT
COVERING THIS NOTE OR SUCH SHARES UNDER SAID ACT AND APPLICABLE STATE SECURITIES LAWS OR THE DELIVERY OF AN OPINION OF COUNSEL
THAT SUCH REGISTRATION IS NOT REQUIRED. THIS NOTE IS ALSO SUBJECT TO RESTRICTIONS ON TRANSFER.

REGEN
BIOPHARMA, INC.

	Issue Date: September 22, 2017	 	Principal Amount:

1.     
Terms. For value received, the Regen BioPharma, Inc., a Nevada corporation (the "Company") hereby absolutely and
unconditionally promises to pay to the order of __________________________(the "Lender") ON DEMAND AT ANY TIME AFTER
October 3, 2020 (the "Maturity Date"), the principal amount of One Hundred thousand dollars ($100,000) and interest on
the whole amount of said principal sum outstanding and remaining from time to time unpaid (the "Note"), commencing from
the date hereof and continuing until payment in full of this Note or conversion as hereinafter provided, at an annual rate equal
to ten percent (10%) simple interest. Interest shall be payable quarterly upon demand or upon conversion pursuant to Section 2
hereunder. Interest shall be computed on the basis of the actual number of days elapsed divided by 365. Principal and interest
shall be payable in lawful money of the United States of America, at the principal place of business of the Lender or at such other
place as the Lender may have designated from time to time in writing to the Company.

2.     
Conversion.

2.1
Conversion Right. The Lender shall have the right from time to time to convert all or a part of the outstanding and unpaid
principal amount of this Note into fully paid and non-assessable shares of Common Stock, as such Common Stock exists on the Issue
Date, or any shares of capital stock or other securities of the Company into which such Common Stock shall hereafter be changed
or reclassified at the conversion price (the "Conversion Price") determined as provided herein (a "Conversion").

The Lender
shall have the right to convert one hundred percent (100%) of the Principal Amount and any accrued interest commencing as of the
date which is the earlier of:

(i) One day subsequent to the execution of an
agreement to a transaction whose completion

would
result in a "Change of Control" of the Company. For purposes of this Note, a Change of Control shall be defined as any
transaction or series of transactions, whether by merger, sale of substantially all of the assets, or sale or transfer of
more than fifty percent (50%) of the outstanding stock of the relevant entity in which the members of the Board of Directors immediately
preceding the closing of the Change of Control transaction no longer constitute a majority of the Board of Directors of the surviving
entity following the closing of such transaction.

(ii)
One day subsequent to the execution of an agreement to a transaction whose completion would result in a "Change of Control"
of KCL Therapeutics, Inc. For purposes of this Note, a Change of Control shall be defined as any transaction or series of transactions,
whether by merger, sale of substantially all of the assets, or sale or transfer of more than fifty percent (50%) of the outstanding
stock of the relevant entity in which the members of the Board of Directors immediately preceding the closing of the Change of
Control transaction no longer constitute a majority of the Board of Directors of the surviving entity following the closing of
such transaction.

(iii) One day
subsequent to the commencement, in compliance with applicable law, of a broad solicitation by a third party to purchase a majority
percentage of the Company's outstanding equity securities for a limited period of time contingent on shareholders of the Company
tendering a fixed number of their equity securities ("Tender Offer").

(iv) One day subsequent to the closing of a Transaction
Event:

"Transaction Event" shall mean either of:

(a) The
sale by the Company or by KCL Therapeutics, Inc. of the Company's proprietary NR2F6 intellectual property to an unaffiliated third
party, or,

(b)  
The granting of a license by the Company or by KCL Therapeutics, Inc. to an unaffiliated third party granting that unaffiliated
third party the right to develop and/or commercialize the Company's proprietary NR2F6 intellectual property

(v)       That
date which is twenty four (24) months subsequent to the date of execution of this Note.

The number
of shares of Common Stock to be issued upon each conversion of this Note shall be determined by dividing the principal amount of
this Note to be converted (the "Conversion Amount") by the applicable Conversion Price as defined in this Section 2 then
in effect on the date specified in the notice of conversion, in the form attached hereto as Exhibit A (the "Notice of Conversion"),
delivered to the Company by the Lender on such conversion date (the "Conversion Date").

 

2.2 Conversion Price. The "Conversion
Price" shall be defined as the lower $0.025 per share, or, a 75% discount to the closing price of the Common Stock on the
Over-the-Counter Bulletin Board on the trading day immediately prior to the date that a Notice of Conversion is submitted pursuant
to Section 2.3. or, if the Over-the-Counter Bulletin Board is not the principal trading market for such security, the closing price
of such security on the principal securities exchange or trading market where such security is listed or traded on the trading
day immediately prior to the date that a Notice of Conversion is submitted pursuant to Section 2.3. or, if no closing bid price
of such security is available in any of the foregoing manners, the average of the closing bid prices of any market makers for such
security that are listed in the "pink sheets" by the National Quotation Bureau, Inc. on the trading day immediately prior
to the date that a Notice of Conversion is submitted pursuant to Section 2.3.

2.3 Method of Conversion. Subject to Section
2.1, this Note may be converted by the Lender by submitting to the Company a Notice of Conversion by facsimile, e-mail or other
reasonable means of communication dispatched on the Conversion Date prior to 5:00 p.m., New York, New York time. The Lender shall
not be required to physically surrender this Note to the Company unless the entire unpaid principal amount of this Note is so converted.
The Lender and the Company shall maintain records showing the principal amount so converted and the dates of such conversions so
as not to require physical surrender of this Note upon each such conversion. In the event of any dispute or discrepancy, such records
of the Company shall, prima facie, be controlling and determinative in the absence of manifest error. Notwithstanding the foregoing,
if any portion of this Note is converted as aforesaid, the Lender may not transfer this Note unless the Lender first physically
surrenders this Note to the Company, whereupon the Company will forthwith issue and deliver upon the order of the Lender a new
Note of like tenor, registered as the Lender (upon payment by the Lender of any applicable transfer taxes) may request, representing
in the aggregate the remaining unpaid principal amount of this Note.

Upon
receipt by the Company from the Lender of a facsimile transmission, e-mail, or other reasonable means of communication of a Notice
of Conversion meeting the requirements for conversion, the Company shall issue and deliver or cause to be issued and delivered
to or upon the order of the Lender certificates for the Common Stock issuable upon such conversion within ten (10) business days
after such receipt. Upon receipt by the Company of a Notice of Conversion, the Lender shall be deemed to be the Lender of record
of the Common Stock issuable upon such conversion, the outstanding principal amount and the amount of accrued and unpaid interest
on this Note shall be reduced to reflect such conversion. All rights with respect to the portion of this Note being so converted
shall forthwith terminate except the right to receive the Common Stock or other securities as herein provided on such conversion.
In lieu of delivering physical certificates representing the Common Stock issuable upon conversion, provided the Company is participating
in the Depository Trust Company ("DTC") Fast Automated Securities Transfer ("FAST") program, upon request of
the Lender, the Company shall use its best efforts to cause its transfer agent to electronically transmit the Common Stock issuable
upon conversion to the Lender by crediting the account of Lender's Prime Broker with DTC through its Deposit Withdrawal Agent Commission
("DWAC") system.

2.4
Concerning the Shares. The shares of Common Stock issuable upon conversion of this Note may not be sold or transferred unless
(i) such shares are sold pursuant to an effective registration statement under the Act or (ii) the Company or its transfer agent
shall have been furnished with an opinion of counsel (which opinion shall be in form, substance and scope customary for opinions
of counsel in comparable transactions) to the effect that the shares to be sold or transferred may be sold or transferred pursuant
to an exemption from such registration or 

(iii) such
shares are sold or transferred pursuant to Rule 144 under the Act (or a successor rule) ("Rule 144") or (iv) such shares
are transferred to an "affiliate" (as defined in Rule 144) of the Company who agrees to sell or otherwise transfer the
shares only in accordance with this Section 2.5 and who is an Accredited Investor as the term Accredited Investor is defined in
Rule 501 of Regulation D, promulgated under the Act.

Subject
to the removal provisions set forth below, until such time as the shares of Common Stock issuable upon conversion of this Note
have been registered under the Act or otherwise may be sold pursuant to Rule 144 without any restriction as to the number of securities
as of a particular date that can then be immediately sold, each certificate for shares of issuable upon conversion of this Note
that has not been so included in an effective registration statement or that has not been sold pursuant to an effective registration
statement or an exemption that permits removal of the legend, shall bear a legend substantially in the following form, as appropriate:

"NEITHER THE ISSUANCE OR SALE OF
THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAS BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE
STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE
REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR (B) AN OPINION OF COUNSEL (WHICH COUNSEL
SHALL BE SELECTED BY THE LENDER), IN A GENERALLY ACCEPTABLE FORM, THAT REGISTRATION IS NOT REQUIRED UNDER SAID ACT."

The
legend set forth above shall be removed and the Company shall issue to the Lender a new certificate therefore free of any transfer
legend if (i) the Company or its transfer agent shall have received an opinion of counsel, in form, substance and scope
customary for opinions of counsel in comparable transactions, to the effect that a public sale or transfer of such Common Stock
may be made without registration under the Act and the shares are so sold or transferred, (ii) such Lender provides the Company
or its transfer agent with reasonable assurances that the Common Stock issuable upon conversion of this Note (to the extent such
securities are deemed to have been acquired on the same date) can be sold pursuant to Rule 144 or (iii) in the case of the Common
Stock issuable upon conversion of this Note, such security is registered for sale by under an effective registration statement
filed under the Act or (iv) otherwise may be sold pursuant to Rule 144 without any restriction as to the number of securities as
of a particular date that can then be immediately sold.

2.5 Reverse
Stock Splits. If the number of shares of Common Stock outstanding at any time while this Note is outstanding is decreased by
a combination of the outstanding shares of Common Stock, then, following the record date of such combination, the Conversion Price
shall be appropriately increased so that the number of shares of Common Stock issuable on conversion hereof shall be decreased
in proportion to such decrease in outstanding shares.

2.6 Stock
Dividends and Stock Splits. If the Company, at any time while this Note is outstanding subdivides outstanding shares of Common
Stock into a larger number of shares then the Conversion price shall be multiplied by a fraction of which the numerator shall be
the number of shares of Common Stock (excluding any treasury shares of the Company) outstanding immediately before such event and
of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event

 

3.     
Payment.

 

WIRE INSTRUCTIONS:

 

4.          
Prepayment. Notwithstanding anything to the contrary contained herein, the Company shall
have the right, exercisable on not less than ten (10) Trading Days prior written notice to the Lender, to prepay the outstanding
Note in part or in full, including outstanding principal and accrued interest. Any notice of prepayment hereunder shall be delivered
to the Lender at its registered addresses and shall state that the Company is exercising its right to prepay the Note and the date
of prepayment, which shall be not more than ten (10) Trading Days from the date of the prepayment notice. Upon receipt of a prepayment
notice, Lender shall have the right, but not the obligation, to accelerate the conversion period specified in Section 2.1 and convert
that portion of the outstanding principal balance which is subject to prepayment to Common Shares as provided for in Section 2.

5.     
Warrant Coverage. In the event that that the Company exercises its right to prepay the
note, or if the Lender chooses not to convert the remaining amount of the note into Common Shares of the company, the Lender shall
receive warrants equal to 10% of the Common shares it would have received had the Lender converted the remaining amount of the
Note into Common shares of the Company. The warrants shall have a strike price of $0.025 per share. See Exhibit B (incorporated
into this Note) for instructions on completing the Exercise of Warrants document.

6.     
Events of Default.

6.1
The following shall constitute events of default (individually an "Event of Default"):

(a)        
default in the payment, when due or payable, of an obligation to pay interest or principal under this Note, which default is not
cured by payment in full of the amount due within thirty (30) days from the date that the Lender receives notice of the occurrence
of such default;

(b)  
filing of a petition in bankruptcy or the commencement of any proceedings under any bankruptcy laws by or against the Company,
which filing or proceeding, is not dismissed within ninety (90) days after the filing or commencement thereof; or

 

(c) failure of
the Company to comply in any way with the terms, covenants or conditions contained in this Note.

6.2 If
an Event of Default shall occur and be continuing, the Lender may, at its option, declare this Note to be immediately due and payable
without further notice or demand, whereupon this Note shall become immediately due and payable without presentment, demand or protest,
all of which are hereby waived by the Company.

7.   
Transfer of Note. This Note may not be transferred or assigned other than a transfer or assignment to an Affiliate of the Lender.
As used herein, the term "Affiliate" means an entity that directly, or indirectly through one or more intermediaries,
controls, or is controlled by, or is under common control with, the Lender.

8.   
Certain Waivers. The Company hereby expressly and irrevocably waives presentment, demand, protest, notice of protest and any
other formalities of any kind.

9.   
Amendment, Modification or Termination. This Note may only be modified, amended, or terminated
(other than by payment in full) by an agreement in writing signed by the Company and the Lender. No waiver of any term, covenant
or provision of this Note shall be effective unless given in writing by the Lender.

10.    
Governing Law. This Note and the obligations of the Company hereunder shall be governed by and interpreted and determined in
accordance with the laws of the State of California (excluding the laws and rules of law applicable to conflicts or choice of law).

 

IN WITNESS
WHEREOF, this Note has been duly executed on behalf of the undersigned on the day and in the year first above written.

	REGEN BIOPHARMA INC	 	 
	 	 	 
	/s/ David R. Koos 	 	 
	David R. Koos, CEO	 	 
	 	 	 
	9/28/ 2017	 	 

 

	 	1	 

    	 

    	 

    

 

EXHIBIT
A

NOTICE
OF CONVERSION

The undersigned hereby elects to convert $ ___________________________
principal amount and

________________ accrued interest of the Note
into that number of shares of Common Stock to be

issued pursuant to the conversion of the Note as set forth
below of REGEN BIOPHARMA, INC. according to the conditions of the convertible note of the Company dated as of September 22, 2017
as of the date written below.

Date of Conversion:

	Applicable Conversion Price	 	 
	(Attach Bloomberg price documentation)	 
	Number of Shares of Common Stock to be Issued Pursuant to Conversion of Note:	 	 
	 	 	 
	Amount of Principal Balance Due Remaining Under the Note After This Conversion:	 	 

Checked box corresponds to applicable instructions:

The Borrower shall electronically
transmit the Common Stock issuable pursuant to this Notice of Conversion to the account of the undersigned or its nominee with
DTC through its Deposit Withdrawal Agent Commission system ("DWAC Transfer").

 

	 	Name of DTC Prime Broker:	 	 
	 	Account Number	 	 

[1 The undersigned hereby
requests that the Borrower issue a certificate or certificates for the number of shares of Common Stock set forth below in the
name(s) specified immediately below or, if additional space is necessary, on an attachment hereto:

	 	Name:	 	 
	 	Address:	 	 
	 	 	 	 
	 	 	 	 
	 	Phone:	 	 

 

	 	 	 	 
	Name	 	Date	 
	Title	 	 	 

 

EXHIBIT
B

COMMON STOCK PURCHASE WARRANT

REGEN BIOPHARMA, INC.

THIS WARRANT AND THE SHARES
ISSUABLE UPON EXERCISE OF THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. THIS WARRANT AND
THE SHARES ISSUABLE UPON EXERCISE OF THIS WARRANT MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF
AN EFFECTIVE REGISTRATION STATEMENT OR APPLICABLE EXEMPTION OR SAFE HARBOR PROVISION.

THIS
COMMON STOCK PURCHASE WARRANT (the "Warrant") certifies that, for value received, Lender is entitled, solely upon the
terms and subject to the limitations on exercise and the conditions hereinafter set forth, to subscribe for and purchase from the
Company, shares of common stock of the Company (the "Warrant Shares"). The purchase price of one Warrant Share under
this Warrant shall be equal to the $0.025 per Warrant Share ("Exercise Price").

 

1.
In the event that Company shall exercise Company's rights pursuant to Section 4 of the Note ("Prepayment Clause") , Lender
shall be entitled , on or prior to the close of business on the three (3) month anniversary of the date that the Note shall have
been prepaid by the Company("Prepayment Date") , to subscribe for and purchase from the Company up to that number of
Warrant Shares at the Exercise Price per Share equivalent to that one tenth of that number of Common Shares that Lender would have
been entitled to be issued had Lender exercised Lender's Conversion Right pursuant to Section 2.1 of the Note as of the Prepayment
Date.

 

2.
In the event that, as of the Maturity Date, part of the outstanding and unpaid principal amount of this Note and any Accrued Interest
remains outstanding, Lender shall be entitled , on or prior to the close of business on the three (3) month anniversary of the
Maturity Date , to subscribe for and purchase from the Company up to that number of Warrant Shares at the Exercise Price per Share
equivalent to that one tenth of that number of Common Shares that Lender would have been entitled to be issued had Lender exercised
Lender's Conversion Right pursuant to Section 2.1 of the Note as of the Maturity Date.

 

3.
If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or
otherwise makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities
payable in shares of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company
upon exercise of this Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines
(including by way of reverse stock split) outstanding shares of Common Stock into a smaller number of shares or (iv) issues by
reclassification of shares of the Common Stock any shares of capital stock of the Company, then in each case the Exercise Price
shall be multiplied by a fraction of which the numerator shall be the number of shares of Common Stock (excluding treasury shares,
if any) outstanding immediately before such event and of which the denominator shall be the number of shares of Common Stock outstanding
immediately after such event, and the number of shares issuable upon exercise of this Warrant shall be proportionately adjusted
such that the aggregate Exercise Price of this Warrant shall remain unchanged. Any adjustment made pursuant to this Section 3 shall
become effective immediately after the record date for the determination of stockholders entitled to receive such dividend or distribution
and shall become effective immediately after the effective date in the case of a subdivision, combination or reclassification

 

4.   
Exercise of the purchase rights represented by this Warrant may be made, in whole or in

part, from and after the initial exercise date, and then at any time, by delivery to the Company (or such other office or agency
of the Company as it may designate by notice in writing to Lender at the address of the Lender appearing on the books of the Company)
of a duly executed facsimile or emailed copy of the Notice of Exercise form annexed hereto and delivery of the aggregate Exercise
Price for the Warrant Shares specified in the applicable Notice of Exercise by wire transfer

 

5.
Warrant Shares purchased hereunder will be delivered to Holder within 10 business days of Notice of Exercise.

6.   
The Warrant Shares may not be sold or transferred unless (i) such shares are sold
pursuant to an effective registration statement under the Act or (ii) the Company or its transfer agent shall have been furnished
with an opinion of counsel (which opinion shall be in form, substance and scope customary for opinions of counsel in comparable
transactions) to the effect that the shares to be sold or transferred may be sold or transferred pursuant to an exemption from
such registration or (iii) such shares are sold or transferred pursuant to Rule 144 under the Act (or a successor rule) ("Rule
144") or (iv) such shares are transferred to an "affiliate" (as defined in Rule 144) of the Company who agrees to
sell or otherwise transfer the shares only in accordance with this Section 6 and who is an Accredited Investor as the term Accredited
Investor is defined in Rule 501 of Regulation D, promulgated under the Act. Subject to the removal provisions set forth below,
until such time as the Warrant Shares have been registered under the Act or otherwise may be sold pursuant to Rule 144 without
any restriction as to the number of securities as of a particular date that can then be immediately sold, each certificate for
Warrant Shares that have not been so included in an effective registration statement or that have not been sold pursuant to an
effective registration statement or an exemption that permits removal of the legend, shall bear a legend substantially in
the following form, as appropriate:

 

"NEITHER
THE ISSUANCE OR SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAS BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN
THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR (B)
AN OPINION OF COUNSEL (WHICH COUNSEL SHALL BE SELECTED BY THE LENDER), IN A GENERALLY ACCEPTABLE FORM, THAT REGISTRATION
IS NOT REQUIRED UNDER SAID ACT."

The
legend set forth above shall be removed and the Company shall issue to the Lender a new certificate therefore free of any transfer
legend if (i) the Company or its transfer agent shall have received an opinion of counsel, in form, substance and scope customary
for opinions of counsel in comparable transactions, to the effect that a public sale or transfer of such securities may be made
without registration under the Act and the shares are so sold or transferred, (ii) such Lender provides the Company or its transfer
agent with reasonable assurances that the Warrant Shares can be sold pursuant to Rule 144 or (iii) such security is registered
for sale by under an effective registration statement filed under the Act or (iv) otherwise may be sold pursuant to Rule 144 without
any restriction as to the number of securities as of a particular date that can then be immediately sold.

 

7. The Lender
shall not be required to physically surrender this Warrant to the Company. If the Lender has purchased all of the Warrant Shares
available hereunder and the Warrant has been exercised in full, this Warrant shall automatically be cancelled without the need
to surrender the Warrant to the Company for cancellation.

 

8. This Warrant
may not be transferred or assigned other than a transfer or assignment to an Affiliate of the Lender. As used herein, the term
"Affiliate" means an entity that directly, or indirectly through one or more intermediaries, controls, or is controlled
by, or is under common control with, the Lender.

 

9. FORM
OF WARRANT NOTICE

NOTICE
OF EXERCISE

TO: REGEN
BIOPHARMA, INC.

The undersigned hereby
elects to purchase_____________ Warrant Shares of the Company pursuant to the terms of the
Warrant issued in connection with that Convertible Note in the amount of _______ by and between________
and the Company dated______ and maturing______ , 2020 and tenders herewith payment of the exercise price in full, together with
all applicable transfer taxes, if any.

Please issue a certificate or certificates
representing said Warrant Shares in the name of the undersigned. The undersigned is an "accredited investor" as defined
in Regulation D promulgated under the Securities Act of 1933, as amended.

[SIGNATURE]

Name:

Date:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00278-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00278-of-00352.parquet"}]]